FCRL6 and cancer: With respect to ‘immunocloaking’ the inhibitory receptors, Fc receptor-like protein 6 (FCRL6) and lymphocyte activation 3 (LAG3) are captured by MHC II on CD4+, CD8+ T cells and NK cells, thus achieving inhibition of immunity against cancer cells expressing MHC II [87,88,89].